Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

23 May 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

carfilzomib Articles

US and European hema-oncologists views therapies for relapsed/refractory multiple myeloma

15 May 2013

Batch of mixed opinions from FDA advisory panels

21 June 2012

Onyx Pharma links with Texas MD Anderson Cancer Center on research

5 June 2012

Onyx falls as FDA says no priority review for cancer drug

13 December 2011

Hematologist-oncologists view Velcade more favorably than Revlimid or Thalomid for multiple myeloma; report

1 November 2011

Onyx Pharma files NDA for multiple myeloma drug carfilzomib

29 September 2011

Onyx Pharma expands Ph III carfilzomib study ahead of EMA filing

30 March 2011

Multiple Myeloma Research Consortium claims it accelerates clinical trial process

8 December 2010

Ono Pharma buys Japanese rights to two cancer drugs in $340 million deal with Onyx

9 September 2010

Showing 1-9 of 9 articles

Go to beginningPrevious
  • 1
NextGo to end
  • Hot Topics
  • Most Read
  • Boehringer Ingelheim gets FDA warning letter on cGMP failures
  • AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
  • Italy's pharma market slump set to continue, warns GlobalData
  • Is failure to adopt business process management putting the pharma industry at risk?
  • Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
  • Boehringer Ingelheim gets FDA warning letter on cGMP failures
  • AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
  • Italy's pharma market slump set to continue, warns GlobalData
  • Is failure to adopt business process management putting the pharma industry at risk?
  • Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS